WAVESUPEX: Analysis of Arterial Waveforms and Oxygen Pressure During Supervised Exercise for Peripheral Artery Disease

Sponsor
University Hospital, Caen (Other)
Overall Status
Recruiting
CT.gov ID
NCT05818046
Collaborator
(none)
36
1
1
9.3
3.9

Study Details

Study Description

Brief Summary

The goal of this observational study is to assess the evolution of oxygen pressure and arterial waveform during supervised exercise therapy in patients with peripheral arterial disease. The main questions it aims to answer are:

  • can a significant increase in oxygen pressure be observed at 3 weeks?

  • can a significant increase of oxygen pressure or arterial waveform be observed at 3, 6 or 9 weeks?

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: transcutaneous oxygen pressure
  • Procedure: Supervised Exercise therapy
N/A

Detailed Description

Peripheral arterial disease (PAD) is a frequent pathology that affects more than 200 million people worldwide, more than 800,000 in France, and is mainly of atheromatous origin. The prevalence of this disease in France is estimated at 11% in people over 40 years of age, with an annual additional cost of €11,000 per patient. Supervised exercise therapy (SET) is the first-line treatment for intermittent claudication PAD for at least 3 months, although 15-20% of patients will not benefit from this therapy. Ankle-Brachial Index, the main diagnostic and monitoring tool for PAD, is not altered during SET. Transcutaneous oximetry (TcPO2) has been used for many years in the diagnosis of chronic permanent ischaemia, in the choice of amputation level and more recently in the diagnosis of proximal PAD.

No studies have investigated the evolution and predictive value of exercise TcPO2 in this context of SET. The assessment of arterial Doppler waveform using an objective classification has also never been performed in the specific context of SET. .

The goal of this observational study is to assess the evolution of oxygen pressure and arterial waveform during supervised exercise therapy in patients with peripheral arterial disease. The main questions it aims to answer are:

  • can a significant increase in oxygen pressure be observed at 3 weeks?

  • can a significant increase of oxygen pressure or arterial waveform be observed at 3, 6 or 9 weeks.

The perspective is to predict the effectiveness of SET in terms of maximum walking distance.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
36 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Screening
Official Title:
Analysis of Arterial Waveforms and Oxygen Pressure During Supervised Exercise for Peripheral Artery Disease
Actual Study Start Date :
Feb 15, 2023
Anticipated Primary Completion Date :
May 10, 2023
Anticipated Study Completion Date :
Nov 25, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Single Group Assignment

intervention consiste to non-invasive arterial assessment by doppler (arterial waveform) and external oxygen probe (Transcutaneous oxygen pressure) at 3,6 and 9 weeks of supervised exercise therapy

Diagnostic Test: transcutaneous oxygen pressure
External proxe fixed to the skin and ultrasound examination.
Other Names:
  • Doppler arterial waveform
  • Procedure: Supervised Exercise therapy
    Supervised exercise therapy consists of three exercise sessions per week for 3 months, combining treadmill walking, lower limb muscle strengthening and stretching exercises. It is considered highly effective for people with leg pain related to peripheral arterial disease and has shown statistically significant improvements in maximum walking distance and quality of life parameters.

    Outcome Measures

    Primary Outcome Measures

    1. Evolution of oximetry at 3 week from baseline [at 3 weeks]

      To describe the evolution of oximetry during SET at 3 weeks from baseline (TcPO2 leg value)

    Secondary Outcome Measures

    1. Evolution of doppler waveform at 3 week from baseline [at 3 weeks]

      To describe the evolution of doppler waveform during SET at 3 weeks from baseline (SB hemodynamic classification)

    2. Evolution of doppler waveform at 6 week from baseline [6 weeks]

      To describe the evolution of doppler waveform during SET at 6 weeks from baseline (SB hemodynamic classification)

    3. Evolution of doppler waveform at 9 week from baseline [9 weeks]

      To describe the evolution of doppler waveform during SET at 9 weeks from baseline (SB hemodynamic classification)

    4. Evolution of doppler waveform at 12 week from baseline [12 weeks]

      To describe the evolution of doppler waveform during SET at 12 weeks from baseline (SB hemodynamic classification)

    5. Evolution of oximetry at 6 week from baseline [at 6 weeks]

      To describe the evolution of oximetry during SET at 6 weeks from baseline (TcPO2 leg value)

    6. Evolution of oximetry at 9 week from baseline [at 9 weeks]

      To describe the evolution of oximetry during SET at 9 weeks from baseline (TcPO2 leg value)

    7. Evolution of oximetry at 12 week from baseline [at 12 weeks]

      To describe the evolution of oximetry during SET at 12 weeks from baseline (TcPO2 leg value)

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • PAD with intermittent claudication

    • SET prescribed

    • ABI < 0.9

    • Beneficiary of French health care insurance

    Exclusion Criteria:
    • PAD with rest ischemia

    • Chronic respiratory failure

    • Acute decompensated disease

    • Lower limb prosthesis

    • Pregnant women and breastfeeding mothers

    • Place of residence more than 100 km from Caen University Hospital

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 CHU Caen Normandie Caen Normandie France 14000

    Sponsors and Collaborators

    • University Hospital, Caen

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    University Hospital, Caen
    ClinicalTrials.gov Identifier:
    NCT05818046
    Other Study ID Numbers:
    • 20-162
    First Posted:
    Apr 18, 2023
    Last Update Posted:
    Apr 18, 2023
    Last Verified:
    Feb 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by University Hospital, Caen
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Apr 18, 2023